Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03794-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Cuicui Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, CTLA-4 Antigen, T-Lymphocytes, Regulatory, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China.
- Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China. xun.gui@mabwell.com.
Zitieren
APA
Guo, C., Dai, X., Du, Y., Xiong, X., & Gui, X. (2024). Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03794-3
Vancouver
Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03794-3
BibTeX
@article{Guo2024,
author = {Guo, Cuicui and Dai, Xiaodong and Du, Yulei and Xiong, Xiumei and Gui, Xun},
title = {Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03794-3}
}
EUVIMED